Delcath Systems

Delcath Systems announces reorganization, 33% of workforce cut

Monday, October 7, 2013 03:54 PM

Delcath Systems, a specialty pharmaceutical and medical device company focused on oncology, has completed a strategic reorganization, eliminating 21 positions, or approximately 33% of its global workforce. The company expects this reorganization, in conjunction with other cost saving measures, to significantly lower cash utilization.

More... »


Delcath selects Quintiles to support EU launch of Chemosat

Wednesday, March 14, 2012 04:47 PM

Delcath Systems, an ongology-focused pharmaceutical company, has selected Quintiles to provide a specialized team of Medical Science Liaisons (MSLs) to support the launch of the Hepatic Chemosat Delivery System for the treatment of cancers in the liver in France, Germany, Italy, Netherlands, Spain, Ireland and the U.K. 

More... »


Delcath appoints Chris Houchins senior VP

Tuesday, February 14, 2012 07:50 AM

Delcath Systems has appointed J. Chris Houchins to the company's clinical development team as senior vice president, clinical and medical affairs.

More... »

Delcath's Ireland location achieves ISO 13485 Certification

Wednesday, December 28, 2011 10:26 AM

Delcath Systems has reported that the company's Galway, Ireland location has achieved ISO 13485:2003 Certification--an internationally recognized quality standard designed to ensure that medical device manufacturers have the necessary comprehensive quality management systems in place to safely design, develop, manufacture and distribute medical devices in the European Union (EU). ISO 13485 Certification is a regulatory requirement of the EU's Medical Device Directive, and represents an important step toward commercialization of the Delcath Hepatic CHEMOSATR Delivery System following its European CE Mark approval in April 2011.

More... »

Delcath names Gores to medical advisory board

Thursday, December 22, 2011 11:57 AM
Delcath Systems has named Gregory Gores, M.D. to the company's medical advisory board.

More... »

Delcath’s phase II liver cancer trial shows promising results

Monday, August 22, 2011 12:45 PM

Delcath Systems has reported encouraging top-line results from the hepatobiliary cohort of the phase II clinical trial of the Delcath chemosaturation system with melphalan in the treatment of patients with unresectable liver cancer.

More... »


CWWeekly

February 23

Venture capital investors funding novel drug R&D three times more than companies repurposing, improving existing drugs

In appreciation: Karen Woodin will be remembered for her teaching, writing and lasting friendships

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

February

Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

January

All eyes on EMA’s adaptive licensing pilot
Sponsors could offer innovative drugs to patients 8 years sooner

Ice Bucket Challenge a boon for ALS research
Donations soar, but phenomenon difficult to replicate

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs